Phenylketonuria (PKU) Clinical Trial
Official title:
- Contribution of Diet Induced Thermogenesis (DIT) and Fat Oxidation to Body Fatness and Body Composition of Patients With Phenylketonuria - Contribution of Physical Activity Energy Expenditure and Energy Intake to Body Fatness and Body Composition of Patients With Phenylketonuria
This will be case-control study investigating whether dietary intake and components of energy expenditure such as Basal metabolic rate (BMR), physical activity energy expenditure (PAEE) and diet induce thermogenesis (DIT) are different between people with phenylketonuria (PKU) and matched healthy controls. Participants will be children and adults with PKU age between 10 to 45 years old, free from history of any acute and chronic illness. Participants will attend the Metabolic Research Unit at New Lister Building (NLB) after 12-hour overnight fasting refraining from alcohol consumption for at least 24 hours. Any planned exercise will be avoided during the 48 hours prior visit to the Metabolic Research Unit. Height, body weight and handgrip strength will be measured upon arrival at the unit. BMR will be assessed and participants will be asked to provide baseline saliva sample followed by consumption of 8 g deuterium water (D2O) diluted in drinking water. Normal or PKU-type isocaloric breakfast meal will then be provided based on intervention group-type. DIT will be measured 5 times for 3 hours, with each measurement lasting for 20 minutes. Two saliva samples will be collected at 3 and 3.5 hours after ingestion of D2O. Participants will be asked to perform an incremental intensity exercise test for 20 minutes on the treadmill during which expired air will be collected and accelerometer counts and heart rate will be measured. Participants will then be trained on how to recorded food intake and how to use accelerometers for habitual physical activity measurements. PKU participants (and their parents if ≤15 years old) will be asked to complete quality of life (QoL) questionnaires. Participants will be required to wear the accelerometer equipment for seven consecutive days excluding bedtime and keep a record of non-wear times. During these days, they will also prospectively record estimated food and beverages intake over four days including one weekend day.
Status | Recruiting |
Enrollment | 26 |
Est. completion date | January 20, 2019 |
Est. primary completion date | January 20, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 10 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Children and adults with PKU between 10 to 45 years old - Free from history of any acute and chronic illness (other than PKU) Exclusion Criteria: - Patients with learning or mobility disabilities - Patients who are deemed not competent to provide informed consent as judged by the clinical staff - Pregnant or lactating women - Participants who are not able to read, comprehend or communicate in English |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University of Glasgow | Glasgow | Scotland |
Lead Sponsor | Collaborator |
---|---|
University of Glasgow |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Basal metabolic rate (BMR) | BMR by means of computerised open-circuit ventilated hood system (Quark RMR®, Italy). | 14 months | |
Primary | Diet induce thermogenesis (DIT) | DIT will be measured by means of computerised open-circuit ventilated hood system (Quark RMR®, Italy). | 14 months | |
Primary | Physical activity energy expenditure (PAEE) | PAEE will be calculated during rest, and continuous incremental exercise by establishing an individual calibration curves for counts accelerometer against rate of oxygen (O2) and rate of carbon dioxide (CO2). | 14 months | |
Primary | Energy and macro-nutrient intake | Participants will be asked to estimate their food intake using household measures or natural unit sizes (e.g. slices of bread) and to record their intake for four days including one weekend day. Data from food diaries will be compared to reference UK photographic atlas of food portion sizes to estimate weight of food intake. Food and energy intake will then be calculated using the dietary software 2010 (The Robert Gordon University, Aberdeen, Scotland, UK). |
14 months | |
Secondary | Body composition | Will be determined using the deuterium water (D2O) dilution technique | 14 months | |
Secondary | Quality of life assessment | PKU participants' quality of life will be assessed by means of validated PKU-specific Health related Quality of Life Questionnaires (PKU-QOL) | 14 months | |
Secondary | Hand-grip strength | Grip strength will be measured by using a hand-grip dynamometer as a measure of strength and physical capacity | 14 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04480567 -
AAV Gene Therapy Study for Subjects With PKU
|
Phase 1/Phase 2 | |
Completed |
NCT03694353 -
Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
|
Phase 3 | |
Completed |
NCT04086511 -
PANDA: PKU Amino Acid Evaluation
|
||
Completed |
NCT02440932 -
Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis
|
N/A | |
Completed |
NCT01617070 -
Effects of Kuvan on Melatonin Secretion
|
Phase 4 | |
Completed |
NCT03505125 -
A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults
|
||
Terminated |
NCT01806051 -
A Pilot Study on Diurnal Variation
|
N/A | |
Recruiting |
NCT05813678 -
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
|
||
Active, not recruiting |
NCT05270837 -
Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria
|
Phase 3 | |
Completed |
NCT01889862 -
Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU
|
Phase 3 | |
Completed |
NCT02009904 -
Simple Breath Test to Examine Phenylalanine Metabolism
|
||
Recruiting |
NCT06305234 -
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
|